Psoriatic Arthritis | Disease Landscape & Forecast | G7 | 2024
The PsA therapy market has become highly dynamic with the recent launches of targeted agents such as AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Upcoming launches in the next few years will further influence the dynamics of the PsA market, challenging the dominance of TNF inhibitors, especially as biosimilars gain acceptance as more cost-effective alternatives to expensive branded therapies, and the emergence of drugs with novel mechanisms of action. IL-17 and IL-23 inhibitors are positioned to garner substantial sales, potentially threatening the current market leaders, given the anticipated stability in diagnosis and drug-treatment rates. The impending entry of the first TYK2 inhibitor (BMS’s deucravacitinib) and an IL-23 inhibitor (Sun Pharma’s tildrakizumab) will also create interesting market dynamics.
Questions answered:
- What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in the markets under study react to these less-expensive therapies?
- How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What are physicians’ perceptions of these therapies?
- Which emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? Which novel mechanisms of action are considered good clinical targets for this disease?
- What unmet needs remain in the treatment of PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?
Content highlights:
Geography: United States, EU5, Japan.
Primary research: 29 country-specific interviews with thought-leading rheumatologists and dermatologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.
Forecast : 10-year, annualized, drug-level sales and patient share of key PsA therapies through 2033, segmented by brands / generics.
Emerging therapies: Phase 3/PR: 3 drugs.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
